Tokai Pharmaceuticals will eliminate approximately 60% of its workforce—about 15 jobs—by the end of the third quarter, in a cost-cutting move announced days after the company’s lead candidate galeterone failed a Phase III trial.

The layoffs, disclosed after the close of the markets on July 29, will leave Tokai with 10 full-time employees. Tokai said it expected to save approximately $4.2 million in annualized operating expenses once the job cuts take full effect.

Employees losing their jobs are being offered severance and outplacement assistance, the company said. Tokai anticipates incurring a charge of approximately $1.3 million in the third quarter related to the reduction, including severance, benefits, and related costs.

“A reduction in force is a very difficult yet necessary step in light of the recent discontinuation of the ARMOR3-SV trial of galeterone in mCRPC [metastatic castration-resistant prostate cancer],” Tokai President and CEO Jodie Morrison said in a statement.

Tokai said it shrunk its workforce to cut costs while it conducts a comprehensive evaluation of strategic options for galeterone and its pipeline.

On July 26, Tokai said galeterone failed the Phase III ARMOR3-SV trial, which compared the candidate to Xtandi® (enzalutamide) in treatment-naïve mCRPC patients whose prostate tumors express AR-V7. The company also said it was terminating the ARMOR3-SV trial.

News of the failure sent the company’s stock crashing 79%, with the closing price falling $5.20 on July 25 to $1.10 the day the trial failure was announced.

Tokai has global development and commercialization rights to galeterone, which uses the mechanistic pathways of current second-generation hormonal therapies, including abiraterone and enzalutamide, while also introducing a unique third mechanism—androgen receptor degradation, which is designed to impair the function of androgen receptors, decreasing their sensitivity to androgen activity and reducing tumor growth.

Previous articlePfizer Acquires Bamboo Therapeutics in a $645M Deal
Next articleUnveiling the Role of an miRNA in an Immune System Tango